Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium fluoride f‑18 is a radiopharmaceutical used as a radioactive diagnostic agent for positron emission tomography (PET) imaging of bone. It consists of the sodium salt of fluorine labeled with the positron-emitting isotope fluorine‑18. After intravenous administration, it accumulates in areas of increased osteogenic activity and bone turnover by exchanging with hydroxyl groups in hydroxyapatite crystals to form fluoroapatite. This property allows sensitive detection and localization of bone metastases, fractures, infections, or other conditions associated with altered bone metabolism. The drug is administered intravenously and emits radiation detectable by PET scanners to produce high-resolution images[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium fluoride f-18.